[HTML][HTML] BRCA mutations in ovarian and prostate cancer: bench to bedside

S Boussios, E Rassy, M Moschetta, A Ghose… - Cancers, 2022 - mdpi.com
Simple Summary DNA damage is one of the hallmarks of cancer. Epithelial ovarian cancer
(EOC)—especially the high-grade serous subtype—harbors a defect in at least one DNA …

[HTML][HTML] BRCA mutations in prostate cancer: assessment, implications and treatment considerations

S Shah, R Rachmat, S Enyioma, A Ghose… - International Journal of …, 2021 - mdpi.com
Prostate cancer ranks fifth in cancer-related mortality in men worldwide. DNA damage is
implicated in cancer and DNA damage response (DDR) pathways are in place against this …

[HTML][HTML] The role of ALDH2 in tumorigenesis and tumor progression: Targeting ALDH2 as a potential cancer treatment

H Zhang, L Fu - Acta Pharmaceutica Sinica B, 2021 - Elsevier
A major mitochondrial enzyme for protecting cells from acetaldehyde toxicity is aldehyde
dehydrogenase 2 (ALDH2). The correlation between ALDH2 dysfunction and …

Prognostic role of DNA damage response genes mutations and their association with the sensitivity of olaparib in prostate cancer patients

D Zhang, X Xu, Y Wei, X Chen, G Li, Z Lu… - Cancer …, 2022 - journals.sagepub.com
Objective Evidence shows that gene mutation is a significant proportion of genetic factors
associated with prostate cancer. The DNA damage response (DDR) is a signal cascade …

[HTML][HTML] Genetic aberrations of DNA repair pathways in prostate cancer: translation to the clinic

A Ghose, M Moschetta, G Pappas-Gogos… - International Journal of …, 2021 - mdpi.com
Prostate cancer (PC) is the second most common cancer in men worldwide. Due to the large-
scale sequencing efforts, there is currently a better understanding of the genomic landscape …

[HTML][HTML] BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis

T Nyberg, M Tischkowitz, AC Antoniou - British journal of cancer, 2022 - nature.com
Background BRCA1 and BRCA2 pathogenic variants (PVs) are associated with prostate
cancer (PCa) risk, but a wide range of relative risks (RRs) has been reported. Methods We …

French AFU Cancer Committee Guidelines-Update 2022-2024: prostate cancer-Diagnosis and management of localised disease

G Ploussard, G Fiard, E Barret, L Brureau… - Progrès en Urologie, 2022 - Elsevier
Objective The objective of the French Urology Association Cancer Committee is to propose
an update of the recommendations for the diagnosis and management of prostate cancer …

Secondary prevention in hereditary breast and/or ovarian cancer syndromes other than BRCA

C Piombino, L Cortesi, M Lambertini… - Journal of …, 2020 - Wiley Online Library
BRCA1‐and BRCA2‐associated hereditary breast and ovarian cancer syndromes are
among the best‐known and most extensively studied hereditary cancer syndromes …

[HTML][HTML] Genetic predisposition to prostate cancer: an update

H Ni Raghallaigh, R Eeles - Familial Cancer, 2022 - Springer
Improvements in DNA sequencing technology and discoveries made by large scale genome-
wide association studies have led to enormous insight into the role of genetic variation in …

Characterization of the cancer spectrum in men with germline BRCA1 and BRCA2 pathogenic variants: results from the consortium of investigators of modifiers of …

V Silvestri, G Leslie, DR Barnes, BA Agnarsson… - JAMA …, 2020 - jamanetwork.com
Importance The limited data on cancer phenotypes in men with germlineBRCA1 and
BRCA2pathogenic variants (PVs) have hampered the development of evidence-based …